# S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

> **NCT00770224** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 87 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **BIOLOGICAL:** tositumomab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** prednisone
- **DRUG:** vincristine
- **RADIATION:** tositumomab

## Key facts

- **NCT ID:** NCT00770224
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2017-04
- **Final completion:** 2019-08
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00770224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00770224, "S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00770224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*